Aytu BioPharma Inc. (AYTU) Financial Statements (2026 and earlier)

Company Profile

Business Address 7900 E. UNION AVENUE
DENVER, CO 80237
State of Incorp. DE
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q3
12/31/2025
Q2
9/30/2025
Q1
6/30/2025
Q4
3/31/2025
Q3
12/31/2024
Q2
9/30/2024
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments30,02532,63030,95218,17320,39820,108
Cash and cash equivalent30,02532,63030,95218,17320,39820,108
Receivables30,92333,22531,15535,82525,40323,159
Inventory, net of allowances, customer advances and progress billings8,65610,10011,43411,05811,08511,739
Inventory8,65610,10011,43411,05811,08511,739
Other current assets     63,05360,738
Other undisclosed current assets6,6375,1545,6387,456(56,886)(55,006)
Total current assets:76,24181,10979,17972,51263,05360,738
Noncurrent Assets
Operating lease, right-of-use asset9591,0101,0611,1111,1781,225
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization484500532546516692
Intangible asset, including goodwill, after accumulated amortization43,57841,43042,20148,71149,95851,205
Intangible asset, excluding goodwill, after accumulated amortization43,57841,43042,20148,71149,95851,205
Other noncurrent assets7389391,2041,3211,5221,971
Total noncurrent assets:45,75943,87944,99851,68953,17455,093
TOTAL ASSETS:122,000124,988124,177124,201116,227115,831
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities54,41549,04248,76553,76851,07147,236
Accounts payable14,25912,34210,60112,04111,69913,513
Accrued liabilities40,15636,70038,16441,72739,37233,723
Debt1,8571,8571,8571,8575,8696,127
Other liabilities2162213,3795,0537,1087,889
Other undisclosed current liabilities9,07514,8739,06310,028  
Total current liabilities:65,56365,99363,06470,70664,04861,252
Noncurrent Liabilities
Long-term debt and lease obligation9,99810,44710,8959,5359,98310,430
Long-term debt, excluding current maturities9,99810,44710,8959,5359,98310,430
Liabilities, other than long-term debt32,23825,37731,2529,06211,43114,323
Other liabilities4,9014,9534,9184,9375,0454,921
Derivative instruments and hedges, liabilities27,33720,42426,3344,1256,3869,402
Total noncurrent liabilities:42,23635,82442,14718,59721,41424,753
Total liabilities:107,799101,817105,21189,30385,46286,005
Equity
Equity, attributable to parent14,20123,17118,96634,89830,76529,826
Common stock111111
Additional paid in capital356,354354,740352,500348,614348,475348,324
Accumulated deficit(342,154)(331,570)(333,535)(313,717)(317,711)(318,499)
Total equity:14,20123,17118,96634,89830,76529,826
TOTAL LIABILITIES AND EQUITY:122,000124,988124,177124,201116,227115,831

Income Statement (P&L) ($ in thousands)

3/31/2026
Q3
12/31/2025
Q2
9/30/2025
Q1
6/30/2025
Q4
3/31/2025
Q3
12/31/2024
Q2
9/30/2024
Q1
Revenues15,16513,88815,13518,45216,22116,574
Cost of revenue
(Cost of Product and Service Sold)
(5,541)(4,702)(4,881)(5,646)(5,435)(4,589)
Gross profit:9,6249,18610,25412,80610,78611,985
Operating expenses(11,594)(10,690)(17,877)(10,385)(12,481)(12,915)
Operating income (loss):(1,970)(1,504)(7,623)2,421(1,695)(930)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
190201(1,230)36140542
Interest and debt expense(560)(516)(730)(900)(1,079)(994)
Income (loss) from continuing operations before equity method investments, income taxes:(2,340)(1,819)(9,583)1,557(2,634)(1,382)
Other undisclosed income (loss) from continuing operations before income taxes(8,244)3,784(9,860)2,2613,0162,880
Income (loss) from continuing operations before income taxes:(10,584)1,965(19,443)3,8183821,498
Income tax expense (benefit)   122283(405)
Other undisclosed loss from continuing operations   (437)   
Income (loss) from continuing operations:(10,584)1,965(19,880)3,9406651,093
Income from discontinued operations     123381
Net income (loss):(10,584)1,965(19,880)3,9407881,474
Other undisclosed net income attributable to parent   6254  
Net income (loss) available to common stockholders, basic:(10,584)1,965(19,818)3,9947881,474
Dilutive securities, effect on basic earnings per share    (2,261)(3,016)(2,880)
Other undisclosed net income (loss) available to common stockholders, diluted  (3,470)8,157   
Net income (loss) available to common stockholders, diluted:(10,584)(1,505)(11,661)1,733(2,228)(1,406)

Comprehensive Income ($ in thousands)

3/31/2026
Q3
12/31/2025
Q2
9/30/2025
Q1
6/30/2025
Q4
3/31/2025
Q3
12/31/2024
Q2
9/30/2024
Q1
Net income (loss):(10,584)1,965(19,880)3,9407881,474
Comprehensive income (loss), net of tax, attributable to parent:(10,584)1,965(19,880)3,9407881,474

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: